
- 1D
- 1W
- 1M
- 1Y
- 5Y
- YTD
About KEZAR LIFE SCIENCES INC
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company is developing small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single. The Company's product portfolio includes KZR-616 and KZR-261. The KZR-616 is a selective immunoproteasome inhibitor being evaluated in Phase II clinical trials in lupus nephritis, dermatomyositis, and polymyositis. In addition, KZR-261 is an anti-cancer clinical candidate targeting the Sec61 translocon and the protein secretion pathway. The Company is focusing its initial development of KZR-616 in severe, chronic and orphan immune-mediated diseases. The Company’s principal operations are in South San Francisco, California.
Stock Analysis
